Actively Recruiting
Identification of Hepatic Fibrosis Using 4D-MRI
Led by University Hospital, Basel, Switzerland · Updated on 2025-03-18
200
Participants Needed
2
Research Sites
282 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a diagnostic/prognostic measure and there is an increasing demand for accurate non-invasive liver stiffness measurement tools. This research project proposes a novel MR-based quantitative Liver Deformation Biomarker (qLDB) approach for non-invasive liver fibrosis assessment by using a new technique called 4D-MRI. 4D-MRI allows to overcome the limitations of currently used techniques. Hence, 4D-MRI may help to identify a novel biomarker for non-invasive staging of liver fibrosis , and therefore improve the final diagnosis of patients suffering from liver diseases.
CONDITIONS
Official Title
Identification of Hepatic Fibrosis Using 4D-MRI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Patients with histologically confirmed chronic liver disease including NAFLD, ALD, viral hepatitis B and C, genetic or autoimmune liver disease
- Patients with acute liver inflammation or cardiac blood congestion to the liver as assessed by laboratory values, imaging findings, and clinical history
- Ability to understand and consent to participate in this study
You will not qualify if you...
- Medical implants such as cardiac pacemaker, pump, or hip prosthesis
- Metallic objects in the body (e.g., splinters after an accident)
- History of brain or cardiac surgery
- Claustrophobia
- Body weight greater than 140 kg or as provided by the MR manufacturer
- Pregnant and lactating women
- Active hepatocellular carcinoma (except patients with history of HCC and curative treatment)
- CHILD C cirrhosis
- Patients with overt ascites unless it resolves with diuretic treatment
- Metabolic syndrome with BMI greater than 30 kg/m2
- Acute or chronic liver disease
- Patients not willing or able to give written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Kantonsspital Baselland (KSL)
Liestal, Basel-Landschaft, Switzerland, 4410
Actively Recruiting
2
University Hospital Basel
Basel, Canton of Basel-City, Switzerland, 4052
Actively Recruiting
Research Team
M
Magdalena Filipowicz Sinnreich, PD Dr.
CONTACT
O
Oliver Bieri, Prof. Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here